Paediatric Haematology-Oncology Unit, Department of Paediatrics.
Departments of Radiodiagnosis.
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e287-e292. doi: 10.1097/MPH.0000000000002148.
Children with cancer are vulnerable to severe infections. Balancing the intensive treatment of cancer, with the potential risk of coronavirus disease-2019 (COVID-19) related morbidity and mortality is a unique challenge. Children with cancer testing positive for severe acute respiratory syndrome coronavirus 2 virus by reverse-transcription polymerase chain reaction at our center were studied. Thirty-seven children tested positive for COVID-19 during the study period. The severity of the illness was mild, moderate, severe, and critical in 10 (27%), 13 (35%), 12 (32%), and 2 (5%) patients, respectively. Of the 14 patients with a severe/critical illness, 2 had oncological emergencies, 4 had dengue co-infection, and 1 had an inguinal bacterial abscess. All patients were discharged in a stable condition. Modification of the treatment protocol was performed in 11 (33%) of 33 patients who were on active treatment for cancer. There was a median delay of 32.5 days to administer the next cycle of chemotherapy in patients who acquired COVID-19 during cancer treatment. Six of 7 patients who were retested after 14 days remained positive by reverse-transcription polymerase chain reaction. Children with cancer with COVID-19 recover with good supportive care. Curative chemotherapy can be administered safely with appropriate modifications in children with cancer with COVID-19.
儿童癌症患者易发生严重感染。平衡癌症的强化治疗与 2019 冠状病毒病(COVID-19)相关发病率和死亡率的潜在风险是一项独特的挑战。对在我中心经逆转录聚合酶链反应检测出严重急性呼吸综合征冠状病毒 2 型病毒阳性的癌症患儿进行了研究。在研究期间,有 37 名儿童 COVID-19 检测呈阳性。疾病严重程度分别为轻度、中度、重度和危重度,分别为 10 例(27%)、13 例(35%)、12 例(32%)和 2 例(5%)。14 例重症/危重症患者中,2 例有肿瘤急症,4 例合并登革热感染,1 例腹股沟细菌性脓肿。所有患者均稳定出院。在 33 例正在接受癌症治疗的患者中,有 11 例(33%)对治疗方案进行了修改。在癌症治疗期间感染 COVID-19 的患者中,接受下一周期化疗的中位延迟时间为 32.5 天。14 天后重新检测的 7 例患者中,有 6 例经逆转录聚合酶链反应仍呈阳性。COVID-19 合并癌症的儿童在接受良好的支持性治疗后可康复。COVID-19 合并癌症的儿童在适当修改治疗方案后可以安全地接受治愈性化疗。